Effectiveness of Pfizer-BioNTech COVID-19 mRNA vaccine against severe illness in the elderly and immunocompromised patients in Finland (RWE_COVID19_2023)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/1000000376
• EU PAS number:
  EUPAS1000000376
• Study ID:
  1000000376
• Official title and acronym:
  Effectiveness of Pfizer-BioNTech COVID-19 mRNA vaccine against severe illness in the elderly and immunocompromised patients in Finland (RWE_COVID19_2023)
• DARWIN EU® study:
  No
• Study countries:
  Finland
• Study description:
  The objective is to study the effectiveness of Pfizer-BioNTech COVID-19 mRNA vaccine against severe COVID-19 disease in the elderly and in immunocompromised patients by using real-world data collected in population-based national health registers in Finland.
• Study status:
  Ongoing

Research institutions and networks

Institutions

FVR – Finnish Vaccine Research

Finland

Study timelines

Date when funding contract was signed

Actual: 06/11/2023

Study start date

Actual: 15/05/2024

Date of final study report

Planned: 31/03/2026

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Pfizer Inc.

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable